TENAX THERAPEUTICS, INC. - TENX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Apr 08, 2026 | SCHEDULE 13G/A | Morgan Stanley | 3.5% | 596,564 | View |
| Apr 08, 2026 | SCHEDULE 13G/A | Morgan Stanley Capital Services LLC | 3.4% | 583,297 | View |
| Apr 07, 2026 | SCHEDULE 13G/A | Ikarian Capital, LLC | 6.7% | 1,145,100 | View |
| Apr 07, 2026 | SCHEDULE 13G/A | Neil Shahrestani | 6.7% | 1,145,100 | View |
| Mar 10, 2026 | SCHEDULE 13D | — | 6.79% | — | View |
| Mar 09, 2026 | SCHEDULE 13G | Logos Global Management LP | 9.9% | 615,000 | View |
| Mar 09, 2026 | SCHEDULE 13G | Logos Global Management GP LLC | 9.9% | 615,000 | View |
| Mar 09, 2026 | SCHEDULE 13G | Logos Global Master Fund LP | 9.9% | 615,000 | View |
| Mar 09, 2026 | SCHEDULE 13G | Logos GP LLC | 9.9% | 615,000 | View |
| Mar 09, 2026 | SCHEDULE 13G | Arsani William | 9.9% | 615,000 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 7.8% | 596,433 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF I GP LLC | 7.8% | 596,433 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 2.3% | 165,382 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF II GP LLC | 2.3% | 165,382 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 9.9% | 761,815 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 9.99% | 768,200 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF INC/IL | 9.99% | 768,200 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | LAMPERT MARK N | 9.99% | 768,200 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Dellora Investments Master Fund LP | 5.7% | 355,257 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Dellora Investments LP | 6.4% | 401,071 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Kevin Pyun | 6.4% | 401,071 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | RTW Investments, LP | 9.9% | 650,968 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Roderick Wong | 9.9% | 650,968 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Point72 Asset Management, L.P. | 6.8% | 423,415 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Point72 Capital Advisors, Inc. | 6.8% | 423,415 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Steven A. Cohen | 6.8% | 423,415 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Perceptive Advisors LLC | 9.1% | 569,308 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Joseph Edelman | 9.1% | 569,308 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Perceptive Life Sciences Master Fund, Ltd. | 9.1% | 569,308 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Venrock Healthcare Capital Partners III, L.P. | 9.9% | 692,959 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | VHCP Co-Investment Holdings III, LLC | 9.9% | 692,959 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Venrock Healthcare Capital Partners EG, L.P. | 9.9% | 692,959 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | VHCP Management III, LLC | 9.9% | 692,959 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | VHCP Management EG, LLC | 9.9% | 692,959 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Nimish Shah | 9.9% | 692,959 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Bong Y. Koh | 9.9% | 692,959 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Lind Global Fund II LP | 6.62% | 442,480 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Lind Global Partners II LLC | 6.62% | 442,480 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | EASTON JEFF | 6.62% | 442,480 | View |
| Feb 12, 2026 | SCHEDULE 13G | Morgan Stanley | 9.6% | 596,376 | View |
| Feb 12, 2026 | SCHEDULE 13G | Morgan Stanley Capital Services LLC | 9.5% | 592,316 | View |
| Dec 23, 2025 | SCHEDULE 13G | Perceptive Advisors LLC | 7.0% | 439,142 | View |
| Dec 23, 2025 | SCHEDULE 13G | Joseph Edelman | 7.0% | 439,142 | View |
| Dec 23, 2025 | SCHEDULE 13G | Perceptive Life Sciences Master Fund, Ltd. | 7.0% | 439,142 | View |
| Dec 08, 2025 | SCHEDULE 13G | JANUS HENDERSON GROUP PLC | 9.99% | 623,733 | View |
| Dec 05, 2025 | SCHEDULE 13G/A | Ikarian Capital, LLC | 15.5% | 967,600 | View |
| Dec 05, 2025 | SCHEDULE 13G/A | Neil Shahrestani | 15.5% | 967,600 | View |
| Nov 14, 2025 | SCHEDULE 13G | Vestal Point Capital, LP | 9.9% | 2,470,096 | View |
| Nov 14, 2025 | SCHEDULE 13G | Ryan Wilder | 9.9% | 2,470,096 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Lind Global Fund II LP | 8.8% | 442,480 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Lind Global Partners II LLC | 8.8% | 442,480 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | EASTON JEFF | 8.8% | 442,480 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Venrock Healthcare Capital Partners III, L.P. | 9.9% | 552,970 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | VHCP Co-Investment Holdings III, LLC | 9.9% | 552,970 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Venrock Healthcare Capital Partners EG, L.P. | 9.9% | 552,970 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | VHCP Management III, LLC | 9.9% | 552,970 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | VHCP Management EG, LLC | 9.9% | 552,970 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Nimish Shah | 9.9% | 552,970 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Bong Y. Koh | 9.9% | 552,970 | View |
| Nov 05, 2025 | SCHEDULE 13G/A | Integrated Core Strategies (US) LLC | 6.9% | 313,712 | View |
| Nov 05, 2025 | SCHEDULE 13G/A | Millennium Management LLC | 6.9% | 313,712 | View |
| Nov 05, 2025 | SCHEDULE 13G/A | Millennium Group Management LLC | 6.9% | 313,712 | View |
| Nov 05, 2025 | SCHEDULE 13G/A | Israel A. Englander | 6.9% | 313,712 | View |
| Oct 29, 2025 | SCHEDULE 13G | Point72 Asset Management, L.P. | 7.4% | 339,633 | View |
| Oct 29, 2025 | SCHEDULE 13G | Point72 Capital Advisors, Inc. | 7.4% | 339,633 | View |
| Oct 29, 2025 | SCHEDULE 13G | Steven A. Cohen | 7.4% | 339,633 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.